Agilent Technologies (A) announced that it will acquire Biocare Medical in a $950 million all-cash deal, aiming to strengthen its position in the fast-growing pathology and cancer diagnostics market. Agilent will acquire Biocare Medical from Excellere Partners and GHO Capital Partners and expects the deal to close by the fourth Fiscal quarter of 2026, subject to customary regulatory approvals and closing conditions.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
For context, Agilent Technologies is a global provider of analytical instruments, software, and services for life sciences, diagnostics, and chemical markets. Meanwhile, Biocare Medical develops antibodies, reagents, and automated tools used in pathology and cancer diagnostics.
What the Deal Means for Agilent
The acquisition is expected to strengthen Agilent’s capabilities in tissue diagnostics and help laboratories access more integrated tools for disease detection and research. Biocare Medical brings more than 300 specialized antibodies and has delivered double-digit revenue and profit growth each year since 2021 and generated over $90 million in revenue in 2025.
After the deal closes, Biocare will become part of Agilent’s Life Sciences and Diagnostics Markets unit. Agilent also expects the acquisition to boost earnings per share within about 12 months.
Notably, Agilent CEO Padraig McDonnell said that combining the two companies’ capabilities will help Agilent better serve pathology customers, speed up innovation, and create long-term value for shareholders.
For Biocare, joining Agilent will expand its scale, accelerate innovation in cancer diagnostics, and improve services for customers and partners.
Is Agilent a Good Stock to Buy?
Turning to Wall Street, analysts have a Strong Buy consensus rating on A stock based on 12 Buys and one Hold assigned in the past three months. The average Agilent’s price target of $163.62 per share implies a 42% upside potential.
Year-to-date, A stock has declined by 15%.
